Quality Assessment of Some Brands of Piroxam Capsules

Main Article Content

Igboasoiyi A. C.
Eseyin O. A.
Oladimeji H. O.
Akpan R. J.


The quality assessment of eleven brands of piroxicam capsules marketed in Nigeria, which included confirmation of their label claims were carried out. Non-aqueous titrimetric evaluation showed that all but two of the brands contained a chemical equivalent of piroxicam within limits of official compendia specifications. However, one of the brands failed the weight uniformity determination as specified by both the British and United States Pharmacopoeia for enteric coated capsules. The dissolution test results were subjected to statistical analyses using a model independent approach employing difference factor (f1) and similarity factor (f2) to compare the dissolution profiles of the brands. The outcome indicated that five out of the eleven brands tested.


Download data is not yet available.

Article Details

How to Cite
NIJOPHASR, A. C., I. . ., O. A., E., H. O. , O., & R. J., A. (2020). Quality Assessment of Some Brands of Piroxam Capsules. Nigerian Journal of Pharmaceutical and Applied Science Research, 1(2). Retrieved from https://nijophasr.net/index.php/nijophasr/article/view/17


Aulton M.E. (2002). Pharmaceutics.The Science of Dosage Form Design. Churchill. Living-Stone London, pp 127-129.

Aulton M.E., (1999). Pharmaceutics.The Science of Dosage Form Design. Churchill Living-Stone, London, pp 154-162

British Pharmacopoeia (1988) `Her Majesty’s Stationary Office, London, pp 996. British Pharmacopoeia (1998). Her Majesty’s Stationary Office ,London, vol.1, pp.1050.

Dartness J., (1998) Essential Drugs Monitor. Managing Drugs Supply, WHO, Geneva 25(6), 1-13

Florey K., (1986) Analytical Profile of Drug Substances. The Squibb Institute for Medical Research, New Brunswick, vol 15, p. 511.

Hardman J.G. and Limbrid L.E. (2001)Goodman and Gilman’s.The Pharmacological Basis of Therapeutics. 9thed. New York, McGraw-Hill, p.713.

Katzung B.G.(2001). Basic and Clinical Pharmacology.8th ed., New York: Lange Medical Books. McGraw-Hill,p. 607.

Moffat A.C., Osselton M.D. and Widdop B. (2004) Clarke’s Analysis of Drugs and Poisons. Vol. II 3rd ed. London: Pharmaceutical Press, pp 1463.

Moghimipour E, Dabbagh M and Zarif F. (2009) Characterization and in vitro Evaluation of Piroxicam Suppositories.Asian Journal of Pharmaceutical and Clinical Research¸2(3), 92-98.

Olaniyi A.A. and Ogungbamila F.O. (1998).Experimental Pharmaceutical Chemistry, Shaneson., Ibadan, pp. 4749.

Stock G. (1997).Practical Pharmacy for Developing Countries.Essential Drugs ,5:1-4.

SweetmanS.C.. (2005).Martindale the Complete Drug Reference , Vol. I 34th ed. London: The Pharmaceutical Press.,pp 84-85.

United States Food and Drug Administration, Center for Drug Evaluation and Research (1997).Guidance for industry: Dissolution testing of immediate release solid oral dosage forms, availableat: http://www.fda.gov/cder/Guidance/1713bp1. pdf . United States Pharmacopoeia XXII, NFXVII, (1990). United State Pharmacopoeia Convention Inc., Rockville, p. 1091.

United States Pharmacopoeia/National Formulary (USP 23/NF 18), (1995).United StatesPharmacopoeia Convention Rockville, p.1235.